views

Physiomics – “Collaboration with The University of Sheffield” announcement. RNS Reach ramptastic?

Describing itself as “a leading mathematical modelling company” in drug development and personalised medicine, Physiomics (PYC) states that it is now “delighted to have been selected by The University of Sheffield to support this highly innovative research program with our analytical and modelling capabilities”. So what’s the detail which has helped the shares up from 2.15p to 2.30p today?

views

Physiomics – “would like to update the market on current trading”. I doubt it ‘would like to’…

Mathematical modelling drug development consultancy Physiomics (PYC) commences a latest update with that it “would like to update the market on current trading”. Good news then?

views

Physiomics – ‘Collaborative Services Agreement’ follows conference participation announcement. Attempted ramptastic?

Mathematical modelling drug development consultancy Physiomics (PYC) has announced a Collaborative Services Agreement, which it states “will expand the scope of our core consulting business to discovery stage projects and improve our access to clients focused on earlier stages of drug development”. So what of a share price currently up to 3p?

views

Physiomics – “ongoing squeeze in biotech funding”. Uh oh...

Previously writing on drug development consultancy Physiomics (PYC), in October with the shares up to 2.6p I noted again a “Contract Award”, again attempted ramptastic… my view remains caveat emptor, Avoid. The shares last closed at 3.75p but are currently more than 25% lower today on the back of a “Trading and Company Update” announcement. So what’s the news?

views

Physiomics – again a “Contract Award”, again attempted ramptastic?

A “Contract Award” announcement from drug development consultancy Physiomics (PYC) and the shares are currently up approaching 24% to 2.60p in response... so clearly material news?

views

Physiomics – “pleased to announce” contract award, attempted ramptastic?

‘Drug treatment regimens and personalised medicine consultancy’ Physiomics (PYC) has followed recent half-year results with a “pleased to announce… third contract by existing client, Numab Therapeutics”. So what of a current 2.3p share price?

views

Physiomics – hiring of new staff to translate to increased revenue? It looks to need to!

Biopharma technology company Physiomics (PYC) has announced its year ended 30th June performance “in-line with market expectations” and expected increased revenue this year. So what of a current share price response more than 5% higher to above 3p?

views

Physiomics has always failed to live up to expectations and I see no reason why that will suddenly change - bargepole!

The lower end of the AIM market seems to be littered with small companies that haven’t made any real progress over the years, in terms of shareholder returns, and I’m often left wondering what the point of them being listed is, given the additional costs that involves.

views

Physiomics – “signs of returning to normality”, so why the share price fall?...

Physiomics (PYC) has updated including “we already see that clinical trials and patient recruitment are showing signs of returning to normality” and “the company's cash position remains strong, and it is estimated that on 30 June 2021 its net asset position will be c.£1.1m, the majority of which is cash”. Why then have the shares currently responded to 5.95p, more than 7% lower?...

NEWSFLOW

Physiomics (#PYC) – FY “ahead of market expectations”, but to still be a loss on income of just “greater than £495k”